Is ARQT or DNLI more profitable?

ARQT runs the higher net margin — ARQT at 6.15% versus DNLI at -14191.20%.

How have ARQT and DNLI total returns compared?

Over the past 5 years, ARQT delivered -0.28% and DNLI delivered -16.91% annualized total return. Past performance doesn't predict future results.

Arcutis Biotherapeutics, Inc. (ARQT) vs Denali Therapeutics Inc. (DNLI)

A side-by-side comparison of Arcutis Biotherapeutics, Inc. and Denali Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ARQT

Arcutis Biotherapeutics, Inc.

$3.05B

$24.35HealthcareDelayed quote: Oct 6, 2026, 12:45 PM EDT

DNLI

Denali Therapeutics Inc.

$3.10B

$19.56HealthcareDelayed quote: Oct 6, 2026, 12:45 PM EDT

Total return — ARQT vs DNLI

growth of $100 · dividends reinvested · last 7y

ARQT +15.4% (+2.1%/yr)DNLI -14.5% (-2.2%/yr)ARQT compounded faster over this window

ARQT DNLI

ARQT vs DNLI: by the numbers

•DNLI is the larger company ($3.10B vs $3.05B market cap).
•ARQT is profitable (6.15% net margin) while DNLI runs a net loss (-14191.20%).

Metrics side by side

Valuation

Metric	ARQT	DNLI
P/E ratio	116.79	N/A
Forward P/E	48.98	N/A
P/S ratio	6.56	861.50
P/B ratio	13.81	3.72
EV / EBITDA	84.02	N/A
FCF yield	1.29%	N/A

Profitability

Metric	ARQT	DNLI
Gross margin	91.14%	0.00%
Operating margin	-3.25%	0.00%
Net margin	6.15%	-14191.20%
ROE	12.93%	-61.24%
ROIC	9.95%	-50.82%

Growth (annualized)

Metric	ARQT	DNLI
Revenue CAGR (5Y)	N/A	20.68%
Total return CAGR (5Y)	-0.28%	-16.91%

Frequently asked

Is ARQT or DNLI more profitable?: ARQT runs the higher net margin — ARQT at 6.15% versus DNLI at -14191.20%.
How have ARQT and DNLI total returns compared?: Over the past 5 years, ARQT delivered -0.28% and DNLI delivered -16.91% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ARQT analysis Full DNLI analysis Interactive comparison tool

Dig into the metrics

Arcutis Biotherapeutics P/E ratio Arcutis Biotherapeutics ROE Denali Therapeutics ROE Arcutis Biotherapeutics operating margin Denali Therapeutics operating margin Arcutis Biotherapeutics revenue growth Denali Therapeutics revenue growth Arcutis Biotherapeutics free cash flow Denali Therapeutics free cash flow

Arcutis Biotherapeutics & Denali Therapeutics appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.